Vnitr Lek 2011, 57(7-8):615-619

Hypertension and cardiovascular complications of chronic renal failure

M. Souček1,*, V. Monhart2, M. Nedbálková1
1 II. interní klinika Lékařské fakulty MU a FN u sv. Anny v Brně, přednosta prof. MUDr. Miroslav Souček, CSc.
2 Interní klinika 1. lékařské fakulty UK a ÚVN Praha, přednosta prof. MUDr. Miroslav Zavoral, Ph.D.

Chronic renal failure is associated with a significant cardiovascular risk due to an increased incidence of cardiovascular risk factors (hypertension, diabetes mellitus, dyslipidemia). Cardiovascular mortality is due to an increased incidence of left ventricular hypertrophy, ischemic heart disease and chronic heart failure. Management focuses on risk factors, mainly high blood pressure in patients with mild to moderate chronic kidney disease, but it often fails in patients with chronic kidney failure.

Keywords: chronic renal failure; cardiovascular complications; arterial hypertension; antihypertensive agents

Received: May 2, 2011; Published: July 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Souček M, Monhart V, Nedbálková M. Hypertension and cardiovascular complications of chronic renal failure. Vnitr Lek. 2011;57(7-8):615-619.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Tesař V. Kardiovaskulární rizikové faktory u chronického selhání ledvin. Kardiol Rev 2009; 11: 111-116.
    2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 (5 Suppl 3): S112-S119. Go to original source... Go to PubMed...
    3. Levey AS, Beto JA, Coronado BE et al. Controling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32: 853-906. Go to original source... Go to PubMed...
    4. National Kidney Foundation. K/DOQI clinical practice quidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (Suppl 2): S1-S266.
    5. Levin A, Thompson CR, Ethier J et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-134. Go to original source... Go to PubMed...
    6. Moran A, Katz R, Jenny NS et al. Left ventricular hyperthrophy in mild and moderate reduction in kidney function determined using cardiac magnetic resonance imaging and cystatin C: the multi-ethnic study of atherosclerosis (MESA). Am J Kidney Dis 2008; 52: 839-845. Go to original source... Go to PubMed...
    7. Levin A, Singer J, Thompson CR et al. Prevalent left ventricular hypertrophy in the predialysis population: identifying oportunities for intervention. Am J Kidney Dis 1996; 27: 347-353. Go to original source... Go to PubMed...
    8. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999; 10: 1606-1611. Go to original source... Go to PubMed...
    9. Parfrey PS, Harnett JD, Foley RN et al. Impact of renal transplantation on uremic cardiomyopathy. Transplantation 1995; 60: 908-914. Go to original source... Go to PubMed...
    10. Shlipak MG, Fried LF, Cushman M et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 2005; 293: 1737-1743. Go to original source... Go to PubMed...
    11. Foley RN, Parfrey PS, Kent GM et al. Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int 1998; 54: 1720-1725. Go to original source... Go to PubMed...
    12. Foley RN, Parfrey PS, Harnett JD et al. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 1995; 5: 2024-2031. Go to original source... Go to PubMed...
    13. Foley RN, Parfrey PS, Morgan J et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58:1325-1335. Go to original source... Go to PubMed...
    14. Goldsmith D, Covic A. Coronary artery disease in uremia: etiology, diagnosis, and therapy. Kidney Int 2001; 60: 2059-2078. Go to original source... Go to PubMed...
    15. Manske CL, Thomas W, Wang Y et al. Screening diabetic transplant candidates for coronary artery disease: identification a low risk subgroup. Kidney Int 1993; 44: 617-621. Go to original source... Go to PubMed...
    16. Koch M, Gradus F, Schoebel FC et al. Relevance of conventional cardiovascular risk factors for the prediction of coronary artery disease in diabetic patients on renal replacement therapy. Nephrol Dia Transplant 2001; 16: 1198-1202.
    17. Parfrey PS, Foley RN, Harnett JD et al. Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int 1996; 49: 1428-1434. Go to original source... Go to PubMed...
    18. Törnig J, Amann K, Ritz E et al. Arteriolar wall thickening, capillary rarefaction and interstitinal fibrosis in the heart of rats with renal failure: the effects of ramipril, nifedipine and moxonidine. J Am Soc Nephrol 1996; 7: 667-675. Go to original source... Go to PubMed...
    19. Chertow GM, Normand SL, Silva LR et al. Survival after acute myocardial infarction in patients with end-stage renal disease: results from the cooperative cardiovascular project. Am J Kidney Dis 2000; 35: 1217-1220. Go to original source... Go to PubMed...
    20. Pidgeon GB, Lynn KL, Bailey RR et al. Coronary angiography prior to renal tranplantation. Nephrology 1995; 1: 59-64. Go to original source...
    21. Kaplan NM, Flynn JT. Kaplan's clinical hypertension. 9th ed. Philadelphia: Lippincott Williams & Wilkins 2006.
    22. Franklin SS, Polez VA, Wong ND et al. Prevalence, treatment, and control of hypertension in U.S. adults, 2001-2002, overall and individually among high cardiovascular disease risk groups. J Hypertens 2006; 24 (Suppl 6): S41.
    23. Monhart V. Hypertenze u chronické renální insuficience. Medicína pro praxi 2009; 6: 73-76.
    24. Mancia G, Laurent S, Agabiti-Rosei E et al. European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-2154. Go to original source... Go to PubMed...
    25. Heerspink HJ, Ninomiya T, Zoungas S et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 2009; 373: 1009-1015. Go to original source... Go to PubMed...
    26. Jacobsen P, Andersen S, Rossing K et al. Dual blockade of the renin-angiotensin system versus maxima recommended dose of ACE inhibitor in diabetic nephropathy. Kidney Int 2003; 63: 1874-1880. Go to original source... Go to PubMed...
    27. Nakao N, Yoshimura A, Morita H et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in nondiabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117-124. Go to original source... Go to PubMed...
    28. Parving H, Persson F, Lewis J et al. for the AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-2446. Go to original source... Go to PubMed...
    29. Levin NW, Handelman GJ, Coresh J et al. Reverse epidemiology; confounding, and inaccurate term. Semin Dial 2007; 20: 586-592. Go to original source... Go to PubMed...
    30. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ et al. Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58th annual fall conference and scientific sessions. Hypertension 2005; 45: 811-817. Go to original source... Go to PubMed...
    31. Goldfarb-Rumyantzev AS, Baird BC, Leypoldt JK et al. The association between BP and mortality in patients on chronic peritoneal dialysis. Nephrol Dial Transplant 2005; 20: 1693-1701. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.